Caption Management, LLC Revance Therapeutics, Inc. Call Options Transaction History

Caption Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$4.65 - $9.31 $1.3 Million - $2.6 Million	-279,500 Reduced 85.06%	49,100 $241,000
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $117,942 - $227,360	20,300 Added 6.58%	328,600 $2.89 Million
Q3 2023 Nov 14, 2023	SELL	$11.47 - $25.07 $3 Million - $6.56 Million	-261,500 Reduced 45.89%	308,300 $3.54 Million
Q2 2023 Aug 14, 2023	SELL	$24.7 - $37.61 $392,730 - $597,999	-15,900 Reduced 2.71%	569,800 $14.4 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $4.78 Million - $9.17 Million	-260,100 Reduced 30.75%	585,700 $18.9 Million

Q4 2022 Feb 14, 2023	SELL	$18.32 - $30.66 $5.78 Million - $9.67 Million	-315,400 Reduced 27.16%	845,800 $15.6 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $16.6 Million - $33.1 Million	1,161,200 New	1,161,200 $31.4 Million

214

83.4M

656K

424K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.